Bristol-Myers Squibb Company (NYSE:BMY) does about 9.12M shares in volume on a normal day but saw 7425367 shares change hands in Monday trading. The company now has a market cap of 154.92B USD. Its current market price is $73.26, marking a decrease of -1.20% compared to the previous close of $74.15. The 52 week high reached by this stock is $81.43 whilst the lowest price level in 52 weeks is $61.19. The script in recent trading has seen the stock touch a high of $74.20 and a low of $72.85.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
Bristol-Myers Squibb Company (BMY) has a 20-day trading average at $72.47 and the current price is -10.04% off the 52-week high compared with 19.73% distance from its 52-week low. The 50-day simple moving average of the closing price is $75.70 and its 200-day simple moving average is $74.53. If we look at the stock’s price movements over the week, volatility stands at 1.64%, which increases to 1.67% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 48.51 to suggest the stock is neutral.
22 analysts observing the Bristol-Myers Squibb Company (BMY) stock have set the 12-month price targets for the company’s shares at between $60.00 and $95.00. The consensus objective for the share price is $82.24, suggesting that the stock has a potential upside of 10.92% over the period. The median price target is 11.73% away from the current levels at $83.00.
FactSet Research has provided data showing that 22 brokerages have issued ratings for the stock. 1 analysts have rated it as a sell, while 1 advise that it is a overweight. 10 analysts have rated it as a buy and 10 have advised that investors hold their positions. The consensus recommendation rating is Overweight and Wall Street’s advice is for investors to Moderate Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on January 17, 2023 when Cantor Fitzgerald initiated the stock to “Overweight” and issued a price target of $95.
The current price level is 1.08%, -3.39%, and -1.72% away from its SMA20, SMA50, and SMA200 respectively, with the BMY price moving above the 50-day SMA on January 23. Bristol-Myers Squibb Company (BMY) stock is up 1.03% over the week and 0.84% over the past month. Its price is 1.82% year-to-date and 13.44% over the past year.
The stock last released its quarterly earnings report for quarter ended 9/29/2022, with the company’s earnings per share (EPS) of $1.99 above consensus estimates by $0.16. The company’s next earnings report is expected on 04/27/2023, with forecasts estimating quarterly EPS at $1.72 and $7.6 for whole year. BMY’s earnings per share are forecast to grow by 1.20% this year and 4.60% over next year. Expected sales for next quarter are $11.66 billion, which analysts say will come at $45.98 billion for the current fiscal year and next year at $47.2 billion. In addition, estimates put the company’s current quarterly revenue at an average of $11.19 billion.
Its 12-month price target is $83.00. To reach the target analysts have set, the stock logically needs to grow 10.92 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $60.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $95.00.
Outstanding shares total 2.13B with insiders holding 0.07% of the shares and institutional holders owning 79.37% of the company’s common stock. The company has a return on investment of 9.40% and return on equity of 20.10%. The price to earnings ratio (P/E ratio) amounts to 23.89 while the forward price to earnings ratio is 9.17. The beta has a value of 0.43. Price to book ratio is 4.78 and price to sales ratio is 3.31.
According to a U.S. Securities and Exchange Commission filing, Vanguard Total Stock Market Index has added its position in Bristol-Myers Squibb Company (BMY) to 64,669,470 shares, mirroring a recent increase by 0.47%. Vanguard Total Stock Market Index added 0.31 million shares of Bristol-Myers Squibb Company common stock bringing its total worth to about $4.65 billion at the end of recent close, SEC documents show. Vanguard Total Stock Market Index isn’t the only investment manager who changed stakes and is followed by Vanguard 500 Index Fund, which added 0.22 million shares to end up with 49,146,912 shares worth $3.54 billion. SPDR S&P 500 ETF Trust cut their holdings by -0.25% in the company over the course of the most recent quarter. It now holds a 1.11% position in Bristol-Myers Squibb Company thanks to 23.51 million shares amounting to $1.69 billion.
